Search - tctmd.com

Displaying 1 - 20 of 344

Sort: Relevancy | Date

Year in Review: DCBs Big in Coronary News, Along With Beta-blockers in STEMI

News Daily News

Year in Review: DCBs Big in Coronary News, Along With Beta-blockers in STEMI

Yael L. Maxwell

December 29, 2025

Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI

News Conference News AHA 2025

Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI

November 09, 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

News Conference News AHA 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

November 08, 2025

The EPIC-CAD Trial

Podcast TCTMD Talking Points

The EPIC-CAD Trial

October 29, 2025

Presentation TCT 2025

TCT 1008: Aspirin vs. Clopidogrel as Monotherapy for Secondary Prevention in Stable Coronary Artery Disease: An Updated Meta Analysis

Presenter: Timothy Charles Shuey

October 27, 2025

Presentation TCT 2025

TCT 995: Less Is More? P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy following PCI In Acute Coronary Syndrome: A Meta-Analysis of Reconstructed Time-to-Event Data

Presenter: Paulo Roberto Tartuce Filho

October 27, 2025

Presentation TCT 2025

TCT 997: Long-Term Clopidogrel vs Aspirin Monotherapy in coronary artery disease patients with High Ischemic Risk: HOST-EXAM Extended Study Post Hoc Analysis

Presenter: Jin-Eun Song

October 27, 2025

Presentation TCT 2025

TCT 474: Edoxaban Monotherapy for Atrial Fibrillation and Stable Coronary Artery Disease in Diabetic Patients: The EPIC-CAD Trial

Presenter: Seunghan Lee

October 27, 2025

Presentation TCT 2025

TCT 56: Impact of age on the efficacy and safety of ticagrelor monotherapy in patients with acute coronary syndrome: A pooled analysis from the TICO and T-PASS Trials

Presenter: Sun Oh Kim

October 26, 2025

Presentation TCT 2025

TCT 55: A Meta-Analysis on Safety and Efficacy of P2Y12 Inhibitor Monotherapy versus Aspirin Monotherapy After 12 Months of DAPT in Patients Post Percutaneous Coronary Intervention

Presenter: Asna Aafreen

October 26, 2025

Presentation TCT 2025

Short-Term Outcomes of Ticagrelor Monotherapy After Primary Percutaneous Coronary Intervention For ST-Elevation Myocardial Infarction

Presenter: Eva Christine Ida Woelders

October 25, 2025

Presentation TCT 2025

Clopidogrel Monotherapy Following 1-Month DAPT vs. Aspirin Monotherapy Following 12-Month DAPT After PCI in ACS Patients: Final 5-Year Results of the STOPDAPT-2 ACS Trial

Presenter: Hirotoshi Watanabe

October 25, 2025

Presentation TCT 2025

Aspirin Monotherapy After 1-Month DAPT in High Bleeding Risk Patients Undergoing PCI: The TARGET SAFE Randomized Trial

Presenter: Miaohan Qiu

October 25, 2025

Bax24: Baxdrostat Successful Again, This Time in Resistant Hypertension

News Daily News

Bax24: Baxdrostat Successful Again, This Time in Resistant Hypertension

October 07, 2025

ALONE-AF: Less Bleeding When OAC Stopped After Successful Ablation

News Conference News ESC 2025

ALONE-AF: Less Bleeding When OAC Stopped After Successful Ablation

September 08, 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

News Conference News ESC 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

September 05, 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

News Conference News ESC 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

September 01, 2025

Presentation ESC 2025

PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET trial

Presenter: Pedro A. Lemos

August 30, 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

News Conference News ESC 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

August 30, 2025

TCTMD's Top 10 Most Popular Stories for August 2025

News Opinion Editor's Corner

TCTMD's Top 10 Most Popular Stories for August 2025

August 28, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.